Literature DB >> 20012408

Neuromuscular disease models and analysis.

Robert W Burgess1, Gregory A Cox, Kevin L Seburn.   

Abstract

Neuromuscular diseases can affect the survival of peripheral neurons, their axons extending to peripheral targets, their synaptic connections onto those targets, or the targets themselves. Examples include motor neuron diseases such as amyotrophic lateral sclerosis, peripheral neuropathies, such as Charcot-Marie-Tooth diseases, myasthenias, and muscular dystrophies. Characterizing these phenotypes in mouse models requires an integrated approach, examining both the nerve and the muscle histologically, anatomically, and functionally by electrophysiology. Defects observed at these levels can be related back to onset, severity, and progression, as assessed by "quality-of-life measures" including tests of gross motor performance such as gait or grip strength. This chapter describes methods for assessing neuromuscular disease models in mice, and how interpretation of these tests can be complicated by the inter-relatedness of the phenotypes.

Entities:  

Mesh:

Year:  2010        PMID: 20012408     DOI: 10.1007/978-1-60761-058-8_20

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  16 in total

1.  Systemic, postsymptomatic antisense oligonucleotide rescues motor unit maturation delay in a new mouse model for type II/III spinal muscular atrophy.

Authors:  Laurent P Bogdanik; Melissa A Osborne; Crystal Davis; Whitney P Martin; Andrew Austin; Frank Rigo; C Frank Bennett; Cathleen M Lutz
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-12       Impact factor: 11.205

2.  Clinical testing and spinal cord removal in a mouse model for amyotrophic lateral sclerosis (ALS).

Authors:  René Günther; Martin Suhr; Jan C Koch; Mathias Bähr; Paul Lingor; Lars Tönges
Journal:  J Vis Exp       Date:  2012-03-17       Impact factor: 1.355

3.  Loss of Clcc1 results in ER stress, misfolded protein accumulation, and neurodegeneration.

Authors:  Yichang Jia; Thomas J Jucius; Susan A Cook; Susan L Ackerman
Journal:  J Neurosci       Date:  2015-02-18       Impact factor: 6.167

4.  Severity of Demyelinating and Axonal Neuropathy Mouse Models Is Modified by Genes Affecting Structure and Function of Peripheral Nodes.

Authors:  Kathryn H Morelli; Kevin L Seburn; David G Schroeder; Emily L Spaulding; Loiuse A Dionne; Gregory A Cox; Robert W Burgess
Journal:  Cell Rep       Date:  2017-03-28       Impact factor: 9.423

5.  A valid mouse model of AGRIN-associated congenital myasthenic syndrome.

Authors:  Laurent P Bogdanik; Robert W Burgess
Journal:  Hum Mol Genet       Date:  2011-09-01       Impact factor: 6.150

6.  T Cells from NOD-PerIg Mice Target Both Pancreatic and Neuronal Tissue.

Authors:  Jeremy J Racine; Harold D Chapman; Rosalinda Doty; Brynn M Cairns; Timothy J Hines; Abigail L D Tadenev; Laura C Anderson; Torrian Green; Meaghan E Dyer; Janine M Wotton; Zoë Bichler; Jacqueline K White; Rachel Ettinger; Robert W Burgess; David V Serreze
Journal:  J Immunol       Date:  2020-09-16       Impact factor: 5.422

7.  Strain-specific hyperkyphosis and megaesophagus in Add1 null mice.

Authors:  Raymond F Robledo; Kevin L Seburn; Anthony Nicholson; Luanne L Peters
Journal:  Genesis       Date:  2012-09-12       Impact factor: 2.487

8.  Lack of neuropathy-related phenotypes in hint1 knockout mice.

Authors:  Kevin L Seburn; Kathryn H Morelli; Albena Jordanova; Robert W Burgess
Journal:  J Neuropathol Exp Neurol       Date:  2014-07       Impact factor: 3.685

9.  Synaptic Deficits at Neuromuscular Junctions in Two Mouse Models of Charcot-Marie-Tooth Type 2d.

Authors:  Emily L Spaulding; James N Sleigh; Kathryn H Morelli; Martin J Pinter; Robert W Burgess; Kevin L Seburn
Journal:  J Neurosci       Date:  2016-03-16       Impact factor: 6.167

10.  Morphological analysis of neuromuscular junction development and degeneration in rodent lumbrical muscles.

Authors:  James N Sleigh; Robert W Burgess; Thomas H Gillingwater; M Zameel Cader
Journal:  J Neurosci Methods       Date:  2014-02-14       Impact factor: 2.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.